Greet Vanhoof

R&d
Beerse, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma.

Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma.

Journal: PLoS genetics

Published: July 19, 2024

Single-cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants.

Single-cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants.

Journal: Clinical and translational medicine

Published: July 10, 2023

Multiplexed multicolor antiviral assay amenable for high-throughput research.

Multiplexed multicolor antiviral assay amenable for high-throughput research.

Journal: Nature communications

Published: February 09, 2023

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.

Journal: HemaSphere

Published: November 07, 2022

[1,2,4]Triazolo[1,5-a]pyrimidine Phosphodiesterase 2A Inhibitors: Structure and Free-Energy Perturbation-Guided Exploration.

[1,2,4]Triazolo[1,5-a]pyrimidine Phosphodiesterase 2A Inhibitors: Structure and Free-Energy Perturbation-Guided Exploration.

Journal: Journal of medicinal chemistry

Published: October 27, 2020

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab.

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab.

Journal: Leukemia

Published: November 19, 2019

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.

Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology

Published: June 22, 2018

Deep Profiling of the Immune System of Multiple Myeloma Patients Using Cytometry by Time-of-Flight (CyTOF).

Deep Profiling of the Immune System of Multiple Myeloma Patients Using Cytometry by Time-of-Flight (CyTOF).

Journal: Methods in molecular biology (Clifton, N.J.)

Published: May 26, 2018

Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5).

Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5).

Journal: Journal of medicinal chemistry

Published: December 24, 2016

Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission.

Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission.

Journal: EJNMMI radiopharmacy and chemistry

Published: November 26, 2015

Identification of a novel orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor with efficacy in animal models of schizophrenia.

Identification of a novel orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor with efficacy in animal models of schizophrenia.

Journal: Journal of medicinal chemistry

Published: December 16, 2014

Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.

Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.

Journal: ACS medicinal chemistry letters

Published: November 08, 2014

Showing 1-12 of 21

Last Updated: 09/26/2026